Epitope characterization of sero-specific monoclonal antibody to clostridium botulinum neurotoxin type a

Hybridoma

Volumn 30, Issue 6, 2011, Pages 503-510

  Corbett, Cindi R ^a,b   Ballegeer, Erin ^a   Weedmark, Kelly A ^a   Elias, M D ^c   Al Saleem, Fetweh H ^c   Ancharski, Denise M ^c   Simpson, Lance L ^c   Berry, Jody D ^a,b  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; BOTULINUM TOXIN A; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY F90G1; MONOCLONAL ANTIBODY F90G2; MONOCLONAL ANTIBODY F90G3; MONOCLONAL ANTIBODY F90G5 3; MONOCLONAL ANTIBODY F93G1; MONOCLONAL ANTIBODY F93G2; MONOCLONAL ANTIBODY F93G3; MONOCLONAL ANTIBODY F93G5; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; BIOASSAY; CLOSTRIDIUM BOTULINUM TYPE A; CONTROLLED STUDY; EPITOPE MAPPING; HIGH THROUGHPUT SCREENING; HYBRIDOMA CELL CULTURE; IMMUNOREACTIVITY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODIES, NEUTRALIZING; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIGEN-ANTIBODY REACTIONS; BOTULINUM TOXINS, TYPE A; CLONING, MOLECULAR; CLOSTRIDIUM BOTULINUM TYPE A; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; EPITOPES; ESCHERICHIA COLI; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; HYBRIDOMAS; MICE; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; TIME FACTORS;

EID: 83455238309     PISSN: 15540014     EISSN: 15578348     Source Type: Journal    
DOI: 10.1089/hyb.2011.0032     Document Type: Article

References (42)

1. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, Lillibridge S, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Swerdlow DL, and Tonat K: Botulinum toxin as a biological weapon: medical and public health management. J Am Med Assoc 2001;285(8):1059-1070 (Pubitemid 32176420)
2. Arnon SS, Schechter R, Maslanka SE, Jewell NP, and Hatheway CL: Human botulism immune globulin for the treatment of infant botulism. New Engl J Med 2006;354(5): 462-471 (Pubitemid 43200297)
3. Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E. Morb. Mortal. Wkly. Rep. 2010; 59(10):299
4. Hibbs RG, Weber JT, Corwin A, Allos BM, Abd el Rehim MS, Sharkawy SE, Sarn JE, and McKee KT Jr: Experience with the use of an investigational F(ab')2 heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt. Clin Infect Dis 1996;23(2):337-340
5. Richardson WH, Frei SS, and Williams SR: A case of type F botulism in southern California. J Toxicol Clin Toxicol 2004; 42(4):383-387 (Pubitemid 39287831)
6. Arnon SS: Creation and development of the public service orphan drug human botulism immune globulin. Pediatrics 2007;119(4):785-789 (Pubitemid 46556679)
7. Centers for Disease Control and Prevention: Centers for Disease Control and Prevention: Botulism in the United States, 1899-1996. Handbook for Epidemiologists, Clinicians, and Laboratory Workers, Atlanta, GA, 1998
8. Lindstrom M, and Korkeala H: Laboratory diagnostics of botulism. Clin Microbiol Rev 2006;19(2):298-314
9. Black JD, and Dolly JO: Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptormediated endocytosis. J Cell Biol 1986;103(2):535-544 (Pubitemid 16055049)
10. Black JD, and Dolly JO: Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves. J Cell Biol 1986;103(2):521-534 (Pubitemid 16055048)
11. Lacy DB, and Stevens RC: Sequence homology and structural analysis of the clostridial neurotoxins. J Mol Biol 1999;291(5):1091-1104 (Pubitemid 29423772)
12. Lacy DB, Tepp W, Cohen AC, DasGupta BR, and Stevens RC: Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol 1998;5(10):898-902 (Pubitemid 28467413)
13. Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, and Chapman ER: SV2 is the protein receptor for botulinum neurotoxin A. Science 2006;312(5773):592- 596
14. Rummel A, Eichner T, Weil T, Karnath T, Gutcaits A, Mahrhold S, Sandhoff K, Proia RL, Acharya KR, Bigalke H, and Binz T: Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the doublereceptor concept. Proc Natl Acad Sci USA 2007;104(1): 359-364 (Pubitemid 46068036)
15. Montecucco C: How do tetanus and botulinum toxins bind to neuronal membranes? Trends Biochem Sci 1986;11(8): 314-317
16. Rummel A, Mahrhold S, Bigalke H, and Binz T: The Hccdomain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction. Mol Microbiol 2004;51(3):631-643 (Pubitemid 38233933)
17. Swaminathan S, and Eswaramoorthy S: Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat Struct Biol 2000;7(8):693-699 (Pubitemid 30636683)
18. Jin R, Rummel A, Binz T, and Brunger AT: Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity. Nature 2006;444(7122):1092-1095 (Pubitemid 46018531)
19. Ravichandran E, Al-Saleem FH, Ancharski DM, Elias MD, Singh AK, Shamim M, Gong Y, and Simpson LL: Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route. Infect Immun 2007;75(6):3043-3054 (Pubitemid 46870189)
20. Nowakowski A, Wang C, Powers DB, Amersdorfer P, Smith TJ, Montgomery VA, Sheridan R, Blake R, Smith LA, and Marks JD: Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci USA 2002;99(17):11346-11350 (Pubitemid 34920928)
21. Pless DD, Torres ER, Reinke EK, and Bavari S: High-affinity, protective antibodies to the binding domain of botulinum neurotoxin type A. Infect Immun 2001;69(1):570-574 (Pubitemid 32040950)
22. Baldwin MR, Tepp WH, Pier CL, Bradshaw M, Ho M, Wilson BA, Fritz RB, Johnson EA, and Barbieri JT: Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E. Infect Immun 2005;73(10):6998-7005 (Pubitemid 41368869)
23. Boles J, West M, Montgomery V, Tammariello R, Pitt MLM, Gibbs P, Smith L, and LeClaire RD: Recombinant C fragment of botulinum neurotoxin B serotype (rBoNTB (HC)) immune response and protection in the rhesus monkey. Toxicon 2006;47(8):877-884 (Pubitemid 43849892)
24. Scotcher MC, Johnson EA, and Stanker LH: Characterization of the epitope region of F1-2 and F1-5, two monoclonal antibodies to botulinum neurotoxin type A. Hybridoma 2009;28(5):315-325
25. Wu H, Yeh C, Huang Y, Tarn L, and Lung C: Characterization of neutralizing antibodies and identification of neutralizing epitope mimics on the Clostridium botulinum neurotoxin Type A. Appl Environ Microbiol 2001;67(7): 3201-3207 (Pubitemid 33644792)
26. Yu R, Wang S, Yu Y, Du W, Yang F, Yu W, and Sun Z: Neutralizing antibodies of botulinum neurotoxin serotype a screened from a fully synthetic human antibody phage display library. J Biomol Screen 2009;14(8):991-998
27. Levy R, Forsyth CM, LaPorte SL, Geren IN, Smith LA, and Marks JD: Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display. J Mol Biol 2007;365(1):196-210 (Pubitemid 44830034)
28. Stanker LH, Merrill P, Scotcher MC, and Cheng LW: Development and partial characterization of high-affinity monoclonal antibodies for botulinum toxin type A and their use in analysis of milk by sandwich ELISA. J Immunol Methods 2008;336(1):1-8
29. Marks JD: Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization. Mov Disord 2004;19(Suppl. 8)
30. Cheng LW, Stanker LH, Henderson II TD, Lou J, and Marks JD: Antibody protection against botulinum neurotoxin intoxication in mice. Infect Immun 2009;77(10):4305-4313
31. Smith TJ, Lou J, Geren IN, Forsyth CM, Tsai R, LaPorte SL, Tepp WH, Bradshaw M, Johnson EA, Smith LA, and Marks JD: Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect Immun 2005;73(9):5450-5457 (Pubitemid 41192979)
32. Corbett CR, Elias MD, Simpson LL, Yuan X-, Cassan RR, Ballegeer E, Kabani A, Plummer FA, and Berry JD: Highthroughput homogeneous immunoassay readily identifies monoclonal antibody to serovariant clostridial neurotoxins. J Immunol Methods 2007;328(1-2):128-138 (Pubitemid 350007628)
33. Berry JD, Jones S, Drebot MA, Andonov A, Sabara M, Yuan XY, Weingartl H, Fernando L, Marszal P, Gren J, Nicolas B, Andonova M, Ranada F, Gubbins MJ, Ball TB, Kitching P, Li Y, Kabani A, and Plummer F: Development and characterisation of neutralising monoclonal antibody to the SARScoronavirus. J Virol Methods 2004;120(1):87-96 (Pubitemid 38968659)
34. Karlsson R, Michaelsson A, and Mattsson L: Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. J Immunol Methods 1991;145(1-2):229-240
35. Mabry R, Rani M, Geiger R, Hubbard GB, Carrion R Jr, Brasky K, Patterson JL, Georgiou G, and Iverson BL: Passive protection against anthrax by using a high-affinity antitoxin antibody fragment lacking an Fc region. Infect Immun 2005;73(12):8362-8368 (Pubitemid 41740327)
36. Gubbins MJ, Berry JD, Corbett CR, Mogridge J, Yuan XY, Schmidt L, Nicolas B, Kabani A, and Tsang RS: Production and characterization of neutralizing monoclonal antibodies that recognize an epitope in domain 2 of Bacillus anthracis protective antigen. FEMS Immunol Med Microbiol 2006; 47(3):436-443 (Pubitemid 44035895)
37. Pearce LB, Borodic GE, First ER, and MacCallum RD: Measurement of botulinum toxin activity: evaluation of the lethality assay. Toxicol Appl Pharmacol 1994;128(1):69-77 (Pubitemid 24289132)
38. Berry JD: Rational monoclonal antibody development to emerging pathogens, biothreat agents and agents of foreign animal disease: the antigen scale. Vet J 2005;170(2):193-211 (Pubitemid 41200520)
39. Chen F, Kuziemko GM, Amersdorfer P, Wong C, Marks JD, and Stevens RC: Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms. Infect Immun 1997;65(5):1626-1630 (Pubitemid 27193578)
40. Garcia-Rodriguez C, Levy R, Arndt JW, Forsyth CM, Razai A, Lou J, Geren I, Stevens RC, and Marks JD: Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat Biotechnol 2007;25(1):107-116 (Pubitemid 46087909)
41. Atassi MZ, and Dolimbek BZ: Mapping of the antibodybinding regions on the HN-domain (residues 449-859) of botulinum neurotoxin A with antitoxin antibodies from four host species. Full profile of the continuous antigenic regions of the H-chain of botulinum neurotoxin A. Protein J 2004; 23(1):39-52 (Pubitemid 41399345)
42. Dolimbek BZ, Aoki KR, Steward LE, Jankovic J, and Atassi MZ: Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/ A. Mol Immunol 2007;44(5):1029-1041 (Pubitemid 44414991)